文献速递腹部CT

钽氧化物纳米颗粒CT对比剂在临床前肝肿瘤检测中的性能

Performance of an Intravascular Tantalum Oxide-Based Nanoparticle Computed Tomography Contrast Agent in Preclinical Hepatic Tumor Detection.
PubMed 文献 · Invest Radiol · 2025-12-01

在VX2肝肿瘤兔模型(n=10)中,经静脉注射540 mg元素(Ta或I)/kg体重的羧基甜菜碱两性离子包覆钽氧化物(TaCZ)纳米颗粒对比剂或碘帕醇后,于临床CT系统上在注射前及注射后40、105、180秒重复扫描,三种读者独立盲法评价114个随机图像序列。TaCZ在各静脉期延迟下均提供更高的肝脏对比增强和肿瘤对比噪声比(CNR),总体敏感度和≤11 mm小肝肿瘤检出率均优于碘帕醇,且在所有亚组中肿瘤清晰度更高。

要点

  • TaCZ在40–180秒各静脉期延迟下肝脏肿瘤CNR均高于碘帕醇(5.7–6.9 vs 3.9–4.5,均P<0.001)。
  • TaCZ总体检出敏感度及≤11 mm小肝肿瘤检出率均优于碘帕醇(均P<0.001及P≤0.002)。
  • 两种对比剂下,病灶越大、对比延迟越早,检出率越高。

核心结论

  • 实验性TaCZ纳米颗粒较碘帕醇提供更高的肝脏对比增强,在全部肿瘤大小和扫描延迟下改善肝肿瘤检出与清晰度,并在延迟静脉期维持强烈增强至少180秒。

研究设计与样本

  • 兔VX2肝肿瘤模型,n=10只兔,每只兔先后接受TaCZ或碘帕醇(540 mg元素(Ta或I)/kg体重)静脉注射,于临床CT系统上在注射前及注射后40、105、180秒重复扫描,对比剂清除后交叉使用另一种对比剂重复成像;以大体病理为参考标准;3名读者独立评价114个随机图像序列。

关键影像表现/征象

  • TaCZ较碘帕醇产生更高的肝脏对比增强,使肝肿瘤在所有受检静脉期延迟下CNR更高(5.7–6.9 vs 3.9–4.5,均P<0.001)。
  • TaCZ在所有亚组中肿瘤清晰度均高于碘帕醇,并在延迟静脉期维持强烈增强至少180秒。
  • 两种对比剂下,病灶较大和对比延迟较早均与更好的病灶检出相关。

诊断标准与关键数值

  • 肿瘤清晰度采用5分制评分(1=几乎不可见至4=明显,0=未检出)。
  • TaCZ总体检出敏感度及≤11 mm肝肿瘤检出率均优于碘帕醇(分别均P<0.001及均P≤0.002)。
  • 按肿瘤大小(3–6 mm、>6–11 mm、>11–14 mm、>14 mm)和静脉期延迟亚组比较两种对比剂的CNR与检出指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Noniodinated intravenous contrast agents have shown significant potential to improve computed tomography (CT) imaging; however, in vivo evidence for impact on lesion detection remains scarce.

PURPOSE: The aim of the study was to compare a novel intravenous carboxybetaine zwitterionic-coated tantalum oxide (TaCZ) nanoparticle contrast agent to clinical iodinated contrast agent for the detection of liver tumors in a rabbit tumor model at CT.

METHODS: Following hepatic implantation of VX2 tumors, n = 10 rabbits were repeatedly scanned on a clinical CT system before and at 40, 105, and 180 seconds after intravenous contrast injection of 540 mg element (Ta or I) per kilogram of body weight using TaCZ or iopamidol. After contrast elimination, imaging was repeated with the other contrast agent in each rabbit. Findings were compared to gross pathology. Three readers independently reviewed n = 114 randomized image series for hepatic tumors and rated conspicuity on a 5-point scale (1 = barely visible to 4 = obvious; 0 = not detected). Regions of interest drawn by readers were used to calculate contrast to noise ratio. Metrics were compared between contrast agents for different tumor size categories (3-6 mm, >6-11 mm, >11-14 mm, >14 mm) and for venous scan delays between contrast agents.

RESULTS: TaCZ provided higher hepatic contrast enhancement resulting in superior Contrast-to-noise ratio (CNR) of hepatic tumors at all examined venous contrast delays (5.7-6.9 vs 3.9-4.5; all P < 0.001) compared to iopamidol. This translated into improved overall sensitivity (all P < 0.001) and detection of small hepatic tumors ≤11 mm (all P ≤0.002). In addition, compared to iopamidol, TaCZ showed higher tumor conspicuity in all subgroups. Larger lesion size and early contrast delay were associated with improved lesion detection for both contrast agents.

CONCLUSIONS: Experimental TaCZ nanoparticles showed higher hepatic contrast enhancement and improved the detection and conspicuity of hepatic tumors at all sizes and scan delays compared to iopamidol, with sustained intense contrast enhancement in delayed venous phase up to at least 180 seconds.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Heimer MM, Sun Y, Bonitatibus PJ, et al. Performance of an Intravascular Tantalum Oxide-Based Nanoparticle Computed Tomography Contrast Agent in Preclinical Hepatic Tumor Detection. Invest Radiol. 2025. PMID: 40100273. doi:10.1097/RLI.0000000000001175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。